Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Box 289, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Br Med Bull. 2011;99:53-71. doi: 10.1093/bmb/ldr029. Epub 2011 Jun 23.
Genetic testing in inherited disease has traditionally relied upon recognition of the presenting clinical syndrome and targeted analysis of genes known to be linked to that syndrome. Consequently, many patients with genetic syndromes remain without a specific diagnosis.
New 'next-generation' sequencing (NGS) techniques permit simultaneous sequencing of enormous amounts of DNA. A slew of research publications have recently demonstrated the tremendous power of these technologies in increasing understanding of human genetic disease.
These approaches are likely to be increasingly employed in routine diagnostic practice, but the scale of the genetic information yielded about individuals means that caution must be exercised to avoid net harm in this setting.
Use of NGS in a research setting will increasingly have a major but indirect beneficial impact on clinical practice. However, important technical, ethical and social challenges need to be addressed through informed professional and public dialogue before it finds its mature niche as a direct tool in the clinical diagnostic armoury.
遗传性疾病的基因检测传统上依赖于对表现出的临床综合征的识别,以及对已知与该综合征相关的基因进行靶向分析。因此,许多患有遗传综合征的患者仍然没有明确的诊断。
新的“下一代”测序(NGS)技术允许同时对大量 DNA 进行测序。最近大量的研究出版物证明了这些技术在加深人类遗传疾病认识方面的巨大力量。
这些方法可能会越来越多地应用于常规诊断实践,但个体所产生的遗传信息量如此庞大,这意味着在这种情况下必须谨慎行事,以免造成实际伤害。
NGS 在研究环境中的应用将对临床实践产生越来越大但间接的有益影响。然而,在其作为临床诊断工具的直接工具成熟之前,需要通过知情的专业和公众对话来解决重要的技术、伦理和社会挑战。